Aegerion Pharmaceuticals (AEGR) Sell-Off on DOJ Investigation 'Excessive', Leerink Partners Says
Tweet Send to a Friend
Leerink Partners analyst Joseph Schwartz reiterated an Outperform rating and $31 price target on Aegerion Pharmaceuticals (NASDAQ: AEGR) calling the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
